iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Holdings is viewed favorably because it leads the sizable U.S. LTCM market with about 72% share, backed by differentiated clinical data, a proprietary ECG dataset, and an underappreciated moat across its algorithm, sensor, and back-office capabilities. Its growth runway remains attractive as the U.S. LTCM market is about 3.5 million tests today and growing in the high-teens, while the broader opportunity expands through upstream PCP and channel-partner penetration, 27 million people at elevated risk in 2025, and a meaningful MCT opening through VitalConnect and Zio MCT. Financially, the business is showing operating leverage with gross margin rising from 67.3% in 2023 to 70.6% in 2025, revenue modeled at $885.9 million in 2026 and $1.028 billion in 2027, and a first full year of profitability expected in 2026.

iRhythm Holdings is facing a weak fundamental setup because it has not made meaningful inroads in the MCT segment, its in-house Zio MCT launch has been repeatedly delayed by regulatory issues, and competitors such as VitalConnect may be cannibalizing its Zio AT and Zio MCT franchises. Its growth opportunity in asymptomatic screening remains opaque and possibly overstated, while reimbursement pressure is a major risk: CMS accounts for about 25% of volumes, ASPs have already declined across products in FY24, and MCT reimbursement has remained vulnerable to further downward pressure. At the same time, unresolved FDA and DOJ scrutiny, including a 2023 FDA warning letter and a CID, creates an overhang that could lead to punitive outcomes, and advances in AI may weaken the company’s algorithmic moat and intensify competition.